With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

New option listings for April 9th include Alumis Inc , LEVERAGE SHARES 2X LONG ASML DAILY ETF (ASMG), Arrivent Biopharma Inc , REX BITCOIN CORPORATE TREASURY CONVERTIBLE BOND (BMA ...

Cartesian Therapeutics Inc. unveiled 12-month efficacy and safety data from the phase IIb trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a ...

FacebookTweetPin It was only yesterday that BlackRock CEO Larry Fink said that “we’re probably in a recession” right now.

KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...

Shares of KalVista Pharmaceuticals (NASDAQ:KALV) spiked in the premarket on Tuesday after the company disclosed a licensing ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Potential Alumis Inc. (NASDAQ:ALMS) shareholders may wish to note that the Independent Director, Alan Colowick, recently bought US$130k worth of stock, paying US$7.04 for each share. Although the ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheetBoards unanimously recommend stockholders ...